DEF 14A: Astria Therapeutics Seeks Stockholder Approval for Amended Stock Incentive Plan and Director Elections at 2024 Annual Meeting

Astria Therapeutics is holding its 2024 Annual Meeting of Stockholders on June 5, 2024, to vote on director elections, an amended stock incentive plan, ratification of the accounting firm, and executive compensation.

Summary

• Astria Therapeutics is convening its 2024 Annual Meeting of Stockholders on June 5, 2024, in Boston.
• Stockholders will vote on the election of three Class III directors, the approval of the second amendment and restatement of the 2015 Stock Incentive Plan, the ratification of Ernst & Young LLP as the independent registered public accounting firm, and an advisory vote on executive compensation.
• The Board of Directors recommends voting in favor of all director nominees and proposals two through four.
• The record date for determining stockholders eligible to vote is April 9, 2024.
• The board is seeking approval to increase the number of shares available under the 2015 Stock Incentive Plan by 5,750,000 shares.
• The board is seeking approval to extend the term of the plan to ten years from the date the second amendment and restatement is approved by our stockholders.

Sentiment

Score: 7

Explanation: The document is generally positive, focusing on corporate governance and incentivizing employees. However, it also acknowledges past net losses and potential dilution.

Positives

• The proposed amendment to the 2015 Stock Incentive Plan aims to attract, retain, and motivate key personnel by providing equity ownership opportunities.
• The company is committed to good corporate governance, with a code of business conduct and ethics and corporate governance guidelines available on its website.
• The Board of Directors is composed of a majority of independent directors.
• The company has a clawback policy in place, compliant with Nasdaq listing standards.
• The company is committed to diversity on its Board of Directors.

Negatives

• Approval of the Second Amended and Restated 2015 Plan will dilute existing shareholders.
• The company has a history of net losses, as indicated in the Pay Versus Performance section.

Risks

• If the Second Amended and Restated 2015 Plan is not approved, the company may face challenges in attracting and retaining key personnel.
• The company's future success depends on its ability to maintain a competitive position in attracting, retaining and motivating individuals who are expected to make important contributions to our company by providing such persons with equity ownership opportunities and performance-based incentives.

Future Outlook

The company believes that the Second Amended and Restated 2015 Plan will serve a critical role in attracting and retaining the high caliber employees essential to our success and in motivating these individuals to strive to enhance our growth.

Management Comments

• The Board of Directors believes that submitting the appointment of Ernst & Young LLP to the stockholders for ratification is good corporate governance.
• The Board of Directors urges you to vote to approve the Second Amended and Restated 2015 Plan.

Industry Context

The document highlights the competitive nature of the life sciences industry, particularly in the Cambridge and Boston, Massachusetts market, emphasizing the need for competitive compensation programs to attract and retain talent.

Comparison to Industry Standards

• The compensation committee uses a peer group of 19 publicly traded biopharmaceutical companies to benchmark executive compensation.
• The peer group is selected based on market capitalization, number of employees, and stage of clinical development.
• The company generally targets the 50th percentile of its peer group for base salaries and bonus targets and the 60th percentile for equity incentive awards.

Corporate Governance

Related Party Transactions

• Affiliates of Perceptive Advisors, LLC, a beneficial owner of more than 5% or our voting securities at that time, purchased 2,481,350 shares of our common stock through the underwriters at the public offering price for an aggregate purchase price of $30.0 million.
• Affiliates of TCG Crossover Fund II, L.P., a beneficial owner of more than 5% or our voting securities at that time, purchased 910,000 shares of our common stock through the underwriters at the public offering price for an aggregate purchase price of $11.0 million.
• Affiliates of Venrock Healthcare Capital Partners III, L.P., a beneficial owner of more than 5% or our voting securities at that time, purchased 910,000 shares of our common stock through the underwriters at the public offering price for an aggregate purchase price of $11.0 million.
• Affiliates of RA Capital, a beneficial owner of more than 5% or our voting securities at that time, purchased 4,135,650 shares of our common stock through the underwriters at the public offering price for an aggregate purchase price of $50.0 million.
• In the October 2023 Financing, affiliates of Fairmount Funds Management LLC, a beneficial owner of more than 5% of our voting securities at that time, purchased 1,652,732 shares of common stock and accompanying common stock warrants to purchase 1,239,549 shares of common stock and pre-funded warrants to purchase up to an aggregate of 650,000 shares of common stock and accompanying common stock warrants to purchase up to an aggregate of 487,500 shares of common stock through the underwriters at the public offering price for an aggregate purchase price of $15.0 million.
• In the October 2023 Financing, affiliates of Perceptive Advisors, LLC, a beneficial owner of more than 5% of our voting securities at that time, purchased 614,062 shares of common stock and accompanying common stock warrants to purchase 460,546 shares of common stock and pre-funded warrants to purchase up to an aggregate of 921,093 shares of common stock and accompanying common stock warrants to purchase up to an aggregate of 690,820 shares of common stock through the underwriters at the public offering price for an aggregate purchase price of $10.0 million.
• In the October 2023 Financing, affiliates of FMR, LLC, a beneficial owner of more than 5% of our voting securities at that time, purchased 855,204 shares of common stock and accompanying common stock warrants to purchase 641,403 shares of common stock through the underwriters at the public offering price for an aggregate purchase price of $5.6 million.
• In the December 2022 Financing, affiliates of Fairmount Funds Management LLC, a beneficial owner of more than 5% of our voting securities at that time, purchased 1,362,398 shares of common stock through the underwriters at the public offering price for an aggregate purchase price of $15.0 million.
• Affiliates of Perceptive Advisors, LLC, a beneficial owner of more than 5% of our voting securities at that time, purchased 908,265 shares of common stock through the underwriters at the public offering price for an aggregate purchase price of $10.0 million.
• Affiliates of Cormorant Global Healthcare Master Fund, LP, a beneficial owner of more than 5% of our voting securities at that time, purchased 908,265 shares of common stock through the underwriters at the public offering price for an aggregate purchase price of $10.0 million.
• Vivo Opportunity LLC, a beneficial owner of more than 5% of our voting securities at that time, purchased 681,199 shares of common stock through the underwriters at the public offering price for an aggregate purchase price of $7.5 million.

Stakeholder Impact

• Approval of the Second Amended and Restated 2015 Plan will impact shareholders through potential dilution.
• The company's compensation policies impact employees and executive officers through base salary, annual cash bonus, long-term equity incentive compensation and other employee benefits.

Next Steps

• Stockholders to vote on the proposals outlined in the proxy statement.
• The company will announce preliminary voting results at the Annual Meeting and publish final results in a Current Report on Form 8-K.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Board of Directors, Director Election, Executive Compensation, Stock Incentive Plan, Ernst & Young, Corporate Governance, Astria Therapeutics